Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor

Area of Science:

• Oncology
• Immunotherapy
• Salivary Gland Neoplasms

Background:

• Primary submandibular gland tumors are rare and present significant treatment challenges due to heterogeneity.
• Existing treatment regimens lack established efficacy for advanced stages.

Observation:

• A patient with stage IV submandibular gland adenocarcinoma and metastases was treated.
• The patient received systemic platinum-based chemotherapy combined with sintilimab (a PD-1 inhibitor).

Findings:

• A complete response of the primary lesion was observed after six cycles of treatment.
• The combination therapy demonstrated significant efficacy in managing advanced disease.

Implications:

• Sintilimab combined with platinum-based chemotherapy shows potential as a first-line treatment for advanced submandibular gland tumors.
• This approach may offer a new therapeutic strategy for rare salivary gland cancers.